ࡱ> e "BbjbjJJ 0(_b(_b:  88888LLL8X<Lo?>>>>>>>$WB El?8"?883)?A A A F88>A >A A 6.9;|E:>??0o?*:yEEyE8;;yE8;A ??`o?yE B :  INSTITUTIONAL REVIEW BOARD Consent for Research Participation Study Title: [Title] Principal Investigator (PI): [Name], [Department], [Institution] Faculty Advisor: [Name], [Department], [Institution] PI Contact Info: [Phone], [Email] __________________________________________________________________ You are being asked to participate in a research study. The first section below highlights key information about this research for you to consider when making a decision whether or not to participate. Carefully consider this information and the more detailed information provided in the remainder of this document. Please ask questions about any of the information you do not understand before you decide whether to participate. KEY INFORMATION ABOUT THE RESEARCH STUDY Voluntary Consent. Taking part in this research project is voluntary. Research studies include only people who choose to take part. You dont have to participate and you can stop at any time. Purpose. The purpose of the study is to [briefly describe study purpose, no more than 2-3 sentences]. Procedures. If you choose to participate, you will be asked to [give brief overview of key study procedures]. Duration. It is expected that your participation will last approximately [period of time duration, number of visits]. Risks. Some of the foreseeable risks or discomforts of your participation may include [describe the most important risks. Consider those most probable and/or highest magnitude of harm. NOTE: if conducting in-person, on-campus human subjects research, you must include under the What Risks Might Result from Being in this Study the COVID-19 risks your participants may encounter by participating in your research study and how those risks will be mitigated]. Benefits. Some of the benefits that may be expected include [insert direct benefits, or if no direct benefit to participant state no direct benefit but the researchers hope to learn/gain xyz]. Alternatives [include only for studies involving an intervention or treatment]. As an alternative to participation, you could [note appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the prospective participant.]. PURPOSE OF THE STUDY [NOTE: If the full purpose is described in the key information summary above, this section may be deleted.] The purpose of this study is [explain research questions and purpose in lay language]. You are being asked to participate because [state the main reason and list the key inclusion/exclusion criteria that may make the individual eligible/ineligible to participate]. 91 [number] people will take part in this research. HOW LONG WILL I BE IN THIS RESEARCH STUDY? [NOTE: If duration is fully detailed in the key information summary above, you may remove this section.] Your participation will last approximately [state the total time of participation. Consider the duration of participation, frequency (if multiple study visits) and provide relevant information in hours, days, weeks, months, years, or until a certain event. Include the number of times the participant will be involved in research activities, how long each activity or session will take, etc.] WHAT WILL HAPPEN IF I TAKE PART IN THIS STUDY? [NOTE: If all procedures/activities are described in the key information summary above, you may remove this section.] If you agree to take part in this study, you will be asked to [provide a detailed description of what the participant will be asked to do in chronological order (what, when, where, how)]. [If you plan to take photographs, and/or if audio and/or video recording devices will be used, explain why the photographs and/or recordings are needed for the research. State whether they can still participate if they do not wish to be recorded or photographed.] [For projects involving the collection of sensitive information or the inclusion of questions that might be upsetting, include examples of the type of questions that will be asked and describe the sensitive topic areas that are involved.] [If applicable, include a statement about whether clinically relevant research results will be shared with the participant and under what conditions. For example: We may learn information about your health as part of the research. We [will/will not] share this information with you [how/why not]]. HOW COULD I BENEFIT FROM BEING IN THIS STUDY? [NOTE: If all benefits are disclosed in the key information summary above, you may remove this section.] The benefits of participation are [describe the probable benefits of participation in the research. Do not include compensation. If there are no direct benefits to the participant, indicate that there are none. Also describe the expected benefits to others: e.g., Information from this study may benefit other people now or in the future by]. WHAT RISKS MIGHT RESULT FROM BEING IN THIS STUDY? [NOTE: if conducting in-person, on-campus human subjects research, you must include the COVID-19 risks your participants may encounter by participating in your research study and how those risks will be mitigated.] There are some risks you might experience from being in this study. They are [in simple, non-scientific language, describe any reasonably foreseeable risks or discomforts. Examples include: Emotional risks (e.g., feelings of sadness or anxiety, embarrassment, guilt) Privacy risks (e.g., disclosure of private information) Social or economic risks (e.g., social ostracizing, discrimination, effects to financial standing, employability, or insurability) Legal risks (e.g., possibility of discovering activities that may require reporting to authorities, possibility of being arrested) Physical risks (e.g., nausea, muscle aches, rashes, infection, discomforts, etc.)] HOW WILL MY PRIVACY AND CONFIDENTIALITY BE PROTECTED? We will take measures to protect your privacy. Despite taking steps to protect your privacy, we can never fully guarantee your privacy will be protected. Measures we will take include [discuss steps that you will take to protect participant privacy (e.g., conduct research in private setting and/or other space consideration, the collection of sensitive information will be limited to the minimum necessary to achieve the aims of the research, allow participant to refuse to answer any question that makes them uncomfortable, discuss security parameters of online survey platforms). Discuss any known limits to protecting privacy (e.g., group participation and knowing who other participants are, etc.).] We will take measures to protect the security of all your personal information, but we can never fully guarantee confidentiality of all study information. Measures we will take include [discuss steps that you will take to protect confidentiality (e.g., whenever feasible, identifiers will be removed from study-related information, and data with identifying information (informed consent, linking list, etc.) will be stored separately from data collected as part of the project; paper-based records will be kept in a secure location and only be accessible to personnel involved in the study, computer-based files will be encrypted and only made available to personnel involved in the study through the use of secure access privileges and passwords, prior to accessing any study-related information; audio and/or video recordings of participants will be transcribed and then destroyed to eliminate audible or visual identification of participants, etc.). Discuss any known limits to protecting confidentiality (e.g., limits of data security and storage, data collected in group settings, etc.)]. WHAT WILL HAPPEN TO THE INFORMATION WE COLLECT ABOUT YOU AFTER THE STUDY IS OVER? Information [and/or specimens] collected for this research will be used to [describe how information will be published and disseminated and whether identifiable information would be included such as the participants name (e.g., We may publish/present the results of this research. However, we will keep your name and other identifying information confidential [OR] With your permission, your name will be used in [e.g., conferences, published reports] about this study.]. We may share your research data with other investigators without asking for your consent again, but it will not contain information that could directly identify you [OR] We will not share your research data with other investigators. [If data must or will be deposited in a public or other repository, briefly describe.] HOW WILL WE COMPENSATE YOU FOR BEING PART OF THE STUDY? You will receive [nature and total amount of incentive/compensation] for your participation in this study. [Describe when and how compensation will be made. If no compensation will be offered for their participation, state so. Describe how compensation will be determined if the participant withdraws from the research before the end of the study.] WHAT OTHER CHOICES DO I HAVE IF I DONT TAKE PART IN THIS STUDY? [Delete this section if not applicable to the study. For projects that involve an intervention that might treat or improve a condition or a disease, describe alternatives to participation in the research study. These could include intervention or treatment available outside the research context. Sample text: There may be other ways of treating your condition if you dont wish to be in this research. Check with your healthcare provider to discuss other options.] VOLUNTARY NATURE OF THE STUDY Taking part in this research study is your decision. Your participation in this study is voluntary. You do not have to take part in this study, but if you do, you can stop at any time. You have the right to choose not to participate in any study activity or completely withdraw from continued participation at any point in this study without penalty or loss of benefits to which you are otherwise entitled. Your decision whether or not to participate will not affect your relationship with the researchers or 91. If you decide to withdraw before this study is completed, [discuss the process for participants to withdraw once the study has begun. State if participants can request their information not be used for research or if there are any limitations to requesting their information be withdrawn. If you are taking photographs or audio or video recording, address how the participants recording will be destroyed. If using online surveys, offer participants an option at the end of the survey to submit their responses, and state if survey is set up such that responses are not saved to the server if a participant chooses not to submit their responses.] [Describe circumstances, if any, under which the participants participation may be terminated by the PI without consent of the participant.] IF YOU ARE INJURED BY THIS RESEARCH [Delete this section if this study is not greater than minimal risk and involves no possibility of injury.] In the event that this research activity results in an injury, treatment will be available, including first aid, emergency treatment, and follow-up care as needed. Care for such injuries will be billed in the ordinary manner, to you or your insurance company. CONTACT INFORMATION FOR QUESTIONS ABOUT YOUR RIGHTS AS A RESEARCH PARTICIPANT The main researcher conducting this study is [name of PI and department, as well as class year if PI is a student] at 91. Please ask any questions you have now. If you have questions later, you may contact [principal investigators name] at [phone number] or [email address] or the faculty advisor for this study, [name of faculty advisor and department] at [phone number] or [email address]. If you have questions or concerns regarding this study and would like to speak with someone other than the researcher, you may contact Mary Hoehn, Institutional Review Board Chair, 91, 815 N. Broadway, Saratoga Springs, NY, 12866, (518) 580-8052,  HYPERLINK "mailto:mhoehn@skidmore.edu" mhoehn@skidmore.edu. STATEMENT OF CONSENT I have had the opportunity to read and consider the information in this form. I have asked any questions necessary to make a decision about my participation. I understand that I can ask additional questions throughout my participation. I understand that by signing below, I volunteer to participate in this research. I understand that I am not waiving any legal rights. I have been provided with a copy of this consent form. I understand that if my ability to consent or assent for myself changes, either I or my legal representative may be asked to re-consent prior to my continued participation in this study. If using audio/video/photography in the research, include the following: As described above, you will be [audio/video recorded and/or photographed] while performing the activities described above. [Recordings/photographs] will be used for [data analysis only/included in conference presentations/used for educational purposes, etc.]. Initial the space below if you consent to the use of [audio/video or photographs] as described. ____ I agree to the use of [audio/video recording or photography] If requesting permission to identify an individual as having participated in the research, include the following: With your permission, your name will be used in [e.g., conferences, published reports] about this study. Initial in the space below if you consent to the use of your name as described. ____ I agree to the use of my name [and any other pieces of information] _______________________ _____________________________ _________ Name of Adult Participant Signature of Adult Participant Date PARENT OR LEGALLY AUTHORIZED REPRESENTATIVE PERMISSION [Delete this section if not applicable to the study. For more than minimal risk research involving children, signature by two parents may be required.] By signing this document, you are agreeing to [your childs OR the persons named below] participation in this study. Make sure you understand what the study is about before you sign. We will give you a copy of this document for your records. We will keep a copy with the study records. If you have any questions about the study after you sign this document, you can contact the study team using the information provided above. I understand what the study is about and my questions so far have been answered. I agree for [my child OR the person named below] to take part in this study. _________________________________________________ Printed Participant Name ___________________________________________________________________ Printed Parent/Legally Authorized Representative Name and Relationship to Participant _________________________________________________ Signature Date     !"FSTUZ\z̵weSB-Be)hf h[)B*CJOJQJ^JaJph/T hf h[)CJOJQJ^JaJ#hf hf 5CJOJQJ^JaJ#hf h[)5CJOJQJ^JaJhf h[)5CJOJQJ^JhwUhKH5CJaJ,h ;hKH5B* CJOJQJ^JaJphnhKH>*B*\phc,h[)hKH5B* CJOJQJ^JaJphnhl75\^JaJ!hMhl7B*CJ^JaJphh d%jh[)5CJUaJmHnHu!"EF\< =  gd[gd[) 7$8$H$gd[) @ gdf $$dNa$gd[) $7$8$H$a$gdgdKH $7$8$H$a$gd[) 7$8$H$gdl7 $7$8$H$a$gdl7z{|< = u U v ߸ߧ߸ߧߗ{{nh[5CJOJQJ^Jh[CJOJQJ^JaJhf h[)5OJQJ\hf h[)5CJOJQJaJ hf hf CJOJQJ^JaJ#hf h[)5CJOJQJ^JaJ)hf h[)B*CJOJQJ^JaJph/T hf h[)CJOJQJ^JaJhf 5CJOJQJ^JaJ$    ( : ; < = > I } ħ|mQ:|mQ:|m-hf h[CJOJQJ^JfHq 6hf h[B*CJOJQJ^JfHph/Tq hf h[CJOJQJ^Jhjh[CJOJQJ^J6hf h[B*CJOJQJ^JfHphq 9hf h[5B*CJOJQJ^JfHphq 0h[B*CJOJQJ^JfHphq "hf h[5CJOJQJ]^Jhf h[5CJOJQJ^J  = > & ' <|}gd<7hgd<7hgdDrl ^gd[gd[  & F gd[gd[ $ % & ' . } *pȱp`P9%9p&hIU5B*CJOJQJ^JaJph/T,h{uhIU5B*CJOJQJ^JaJph/ThIUB*CJOJQJ^Jph/Th[B*CJOJQJ^Jph/T%hf h[B*CJOJQJ^Jph/Thf h[5CJOJQJ^Jhf h[CJOJQJ^Jhjh[CJOJQJ^J-hf h[CJOJQJ^JfHq 6hf h[B*CJOJQJ^JfHph/Tq 6hf h[B*CJOJQJ^JfHphq 0doѴфufVD/(hUh[5B*CJOJQJ^Jph/T"h[5B*CJOJQJ^Jph/Thf h[5CJOJQJ^Jhf h[CJOJQJ^Jhjh[CJOJQJ^J%hf h[B*CJOJQJ^Jph/T9hf h[5B*CJOJQJ^JfHphq 9hf h[5B*CJOJQJ^JfHphq hf h[CJOJQJ^Jhjh[CJOJQJ^Jh[B*CJOJQJ^Jph/T4<Y[ӠzhQ<')hf hClB*CJOJQJ^JaJph/T)hf h dB*CJOJQJ^JaJph/T,hf hClB*CJOJQJ\^JaJph/T#hf hClCJOJQJ\^JaJ)hUh<7hB*CJOJQJ^JaJph/T hf h dCJOJQJ^JaJ&hf hDrl5CJOJQJ\^JaJh[CJOJQJ^J%hUh[B*CJOJQJ^Jph/Thf h[CJOJQJ^Jhf h[5CJOJQJ^Jh[5CJOJQJ^J(3DKS{|}/=@ABﮝzzfR=)hUhwX%B*CJOJQJ^JaJph/T&hf h d5CJOJQJ\^JaJ&hf hDrl5CJOJQJ\^JaJ hf hf CJOJQJ^JaJ#hf h<7h5CJOJQJ^JaJ hf h dCJOJQJ^JaJ,hf h d6B* CJOJQJ^JaJphp)hUhjB*CJOJQJ^JaJph/T)hUh<7hB*CJOJQJ^JaJph/T hf h<7hCJOJQJ^JaJAB %&TK#0hn & FgdgdgdSqgd~=gd4gd~=gdDrlgd<7hBk Ű܍x_F_xܰ4#hjB*CJOJQJ^JaJph/T0hf hSq0J5B*CJOJQJ^JaJph/T0hf h.0J5B*CJOJQJ^JaJph/T)hUh.B*CJOJQJ^JaJph/T hf h.CJOJQJ^JaJ#hEvB*CJOJQJ^JaJph/T)hf hDrlB*CJOJQJ^JaJph/T,hf hDrlB*CJOJQJ\^JaJph/T hf hDrlCJOJQJ^JaJ#hf hDrlCJOJQJ\^JaJhs!"#$%&T"ղՠՠՋydR83hf h~=0J5B*CJOJQJ\^JaJph/T#hf h~=CJOJQJ\^JaJ)hf h4B*CJOJQJ^JaJph/T#hf h~=5CJOJQJ^JaJ)hf h WB*CJOJQJ^JaJph/T#hm`B*CJOJQJ^JaJph/T#hEvB*CJOJQJ^JaJph/T hf hDrlCJOJQJ^JaJ)hf hDrlB*CJOJQJ^JaJph/T)hf hwUB*CJOJQJ^JaJph/T"?JKL˱˄nZF1)hUhSqB*CJOJQJ^JaJph/T&hf h d5CJOJQJ\^JaJ&hf h~=5CJOJQJ\^JaJ*hf h~=0J5CJOJQJ\^JaJ*hf h W0J5CJOJQJ\^JaJ-hj0J5B*CJOJQJ\^JaJph/T3hf hwU0J5B*CJOJQJ\^JaJph/T3hf h~=0J5B*CJOJQJ\^JaJph/T3hf h W0J5B*CJOJQJ\^JaJph/T LR "#prҾ驔kQ7Q3hUhSq0J5B*CJOJQJ\^JaJph/T3hUh0J5B*CJOJQJ\^JaJph/T,hUh~=B*CJOJQJ\^JaJph/T#hf h~=CJOJQJ\^JaJ)hUh dB*CJOJQJ^JaJph/T)h{uhSqB*CJOJQJ^JaJph/T&hIU5B*CJOJQJ^JaJph/T,h{uh{u5B*CJOJQJ^JaJph/T,h{uhSq5B*CJOJQJ^JaJph/T .0h{gS?. hf h dCJOJQJ^JaJ&hf h d5CJOJQJ\^JaJ&hf h>5CJOJQJ\^JaJ&hf hwU5CJOJQJ\^JaJ6hf h0J56B* CJOJQJ\^JaJphp3hf h W0J5B*CJOJQJ\^JaJph/T3hf hSq0J5B*CJOJQJ\^JaJph/T3hf h|?0J5B*CJOJQJ\^JaJph/T3hf h0J5B*CJOJQJ\^JaJph/T!!&&U&V&)(3(4())v)w))) ++O+P+$-gd$EgdwX%gd>gd WgdgdjgdwUgd  ? !!!!@!!ɲmYmYE1&hB*CJOJQJ\^JaJph/T&h{B*CJOJQJ\^JaJph/T&hjB*CJOJQJ\^JaJph/T,hjhjB*CJOJQJ\^JaJph/T,hf hf B*CJOJQJ\^JaJph/T,hf h>B*CJOJQJ\^JaJph/T,hf h.B*CJOJQJ\^JaJph/T#hf h.CJOJQJ\^JaJ#hf h>CJOJQJ\^JaJ#hf hf CJOJQJ\^JaJ!!!!!!!!t""# ###-#վվխr`K6)hf hSqB*CJOJQJ^JaJph/T)hUhB*CJOJQJ^JaJph/T#hB*CJOJQJ^JaJph/T)hjhB*CJOJQJ^JaJph/T)hUh.B*CJOJQJ^JaJph/T hf h.CJOJQJ^JaJ hf hwUCJOJQJ^JaJ,hf h.B*CJOJQJ\^JaJph/T,hf h>B*CJOJQJ\^JaJph/T&hQ B*CJOJQJ\^JaJph/T-#3#R#T###### $ $f$g$$$$$$%;%<%`%k%l%m%&&V&ƴƟxgU#hf h W5CJOJQJ^JaJ hf h WCJOJQJ^JaJ)hUh.B*CJOJQJ^JaJph/T#hEvB*CJOJQJ^JaJph/T)hjhB*CJOJQJ^JaJph/T#hB*CJOJQJ^JaJph/T)hf hSqB*CJOJQJ^JaJph/T#h9`B*CJOJQJ^JaJph/T#hMB*CJOJQJ^JaJph/TV&b&t&&!','.'<'''''''/(0(1(2(3(4(6((((ڰڰڙڰwbwQ@Q hf hwX%CJOJQJ^JaJ hf h WCJOJQJ^JaJ)hUh WB*CJOJQJ^JaJph/T hf hf CJOJQJ^JaJ hf hQ CJOJQJ^JaJ,hf hQ 5B*CJOJQJ^JaJph/T)hUhf B*CJOJQJ^JaJph/T)hUhEvB*CJOJQJ^JaJph/T)hUh>B*CJOJQJ^JaJph/T hf h>CJOJQJ^JaJ(((()))u)v)w))))زeQ=)&hf h|?5CJOJQJ\^JaJ&hf h 5CJOJQJ\^JaJ&hf h W5CJOJQJ\^JaJ3hf hCj0J56B* CJOJQJ^JaJphp:hf h WB*CJOJQJ^JaJfHphq )hf h>B*CJOJQJ^JaJph/T)hf hwX%B*CJOJQJ^JaJph/T hf hf CJOJQJ^JaJ hf h WCJOJQJ^JaJ,hf h W5B*CJOJQJ^JaJph/T )))**M******* ++O+P++ֿ}ֿiW@,hf hwX%5B*CJOJQJ^JaJph/T#hf hwX%CJOJQJ\^JaJ&hf hwX%5CJOJQJ\^JaJ&hEvB*CJOJQJ\^JaJph/T,hf h4B*CJOJQJ\^JaJph/T,hf hf B*CJOJQJ\^JaJph/T,hf hwX%B*CJOJQJ\^JaJph/T,hf h WB*CJOJQJ\^JaJph/T#hf h WCJOJQJ\^JaJ++$-%-B-D-U///122^2i2k2l2ӼwbMb;b;b+hf h d5OJQJ^JaJ"hEv5B*OJQJ^JaJph/T(hf h45B*OJQJ^JaJph/T(hf hN,5B*OJQJ^JaJph/Thf hN,5OJQJ^JaJhf h45OJQJ^JaJ hf h dCJOJQJ^JaJ&hf h d5CJOJQJ\^JaJ,hf h|?6B* CJOJQJ^JaJphp,hf hwX%B*CJOJQJ\^JaJph/T)hf hwX%B*CJOJQJ^JaJph/T$-%-C-D-T/U/11l2n22244U4V4555767K7L788gd{ ^`gd Wgdgd|?gdwX% 0^`0gd~:~gd W $@&a$gd|?l2m2n2222222244ʹzeP>- hf h|?CJOJQJ^JaJ#hf h dCJOJQJ\^JaJ)hf hwX%B*CJOJQJ^JaJph/T)hf h WB*CJOJQJ^JaJph/T,hf h45B*CJOJQJ^JaJph/T,hf h W5B*CJOJQJ^JaJph/T hf hCJOJQJ^JaJ hf h dCJOJQJ^JaJ&hf h|?5CJOJQJ\^JaJ hf hdWCJOJQJ^JaJ hf hNFCJOJQJ^JaJ 444T4U4V4Z4i4444444435ű|jS>-| hf h NCJOJQJ^JaJ)hf h WB*CJOJQJ^JaJph/T,hf h WB*CJOJQJ\^JaJph/T#hf h1+CJOJQJ\^JaJ#hf h NCJOJQJ\^JaJ#hf h|?CJOJQJ\^JaJ hf h|?CJOJQJ^JaJ&hf h|?5CJOJQJ\^JaJ&hf h W5CJOJQJ\^JaJ hf h WCJOJQJ^JaJ)hf h|?B* CJOJQJ^JaJphp35R5V5W5c5d5e5h5i5v5w5x5555555555H6e66666ٳꞍ|jXFXjXj#hf h NCJOJQJ\^JaJ#hf h|?CJOJQJ\^JaJ#hf h WCJOJQJ\^JaJ hf h|?CJOJQJ^JaJ hf h WCJOJQJ^JaJ)hf h WB*CJOJQJ^JaJph/T hf hsjCJOJQJ^JaJ)hf hsjB*CJOJQJ^JaJph/T hf h NCJOJQJ^JaJ)hf h NB*CJOJQJ^JaJph/T66666772737475767C7J7K7L77ɲ۲ۍ~o`L:#h{h{CJOJQJ\^JaJ&hf h d5CJOJQJ\^JaJhf h dOJQJ^JaJhf h WOJQJ^JaJhf hf OJQJ^JaJ hf hCJOJQJ^JaJ'hf h|?0JCJOJQJ\^JaJ,jhf h|?CJOJQJU\^JaJ#hf h WCJOJQJ\^JaJ#hf h|?CJOJQJ\^JaJ#hf hCJOJQJ\^JaJ7788788888 99u9v9}9~999999:F:f:g:x:::;;7;S;a;b;c;~;;;;𸡸޸޸޸{m\{m h{hEvCJOJQJ^JaJh{CJOJQJ^JaJ)hUh{B*CJOJQJ^JaJph/T h{h{CJOJQJ^JaJ,hUhEvB*CJOJQJ\^JaJph/T,hUh{B*CJOJQJ\^JaJph/ThEvCJOJQJ\^JaJ#h{h{CJOJQJ\^JaJh{CJOJQJ\^JaJ$88989999b;c;;;<<<<==g======{>|>*@+@@@@gd WgdXgd{;<I<p<<<<<<===g=========>{>>>>>5?8?p?ٽٽٽٽٽn]nn]K]#hm`hm`CJOJQJ\^JaJ hf h WCJOJQJ^JaJ)hf h WB*CJOJQJ^JaJph/T,hf h W5B*CJOJQJ^JaJph/T#hf h W5CJOJQJ^JaJ hf h{CJOJQJ^JaJh{CJOJQJ^JaJhEvCJOJQJ^JaJ h{h{CJOJQJ^JaJ)hUh{B*CJOJQJ^JaJph/Tp?s?+@@@@@@@@AAAABBBBBBBBBB!B"Bʳ܉{{iXPLPLPLPLXhjhU hf hRCJOJQJ^JaJ#hf h W5CJOJQJ^JaJhEvCJOJQJ^JaJ#hf h WCJOJQJ]^JaJ/hf h W56B*CJOJQJ^JaJph/T,hf h W6B*CJOJQJ^JaJph/T#hf h W6CJOJQJ^JaJ hf h WCJOJQJ^JaJ#hm`hm`CJOJQJ\^JaJ@AA\AAAAABBBBBBBBBB B!B"BgdRgd W6&P1h:pO/ =!"#$% F ݄"w7"DLJFIFddDucky<Adobed       R  !1A"ӤUQaq2B#tRb3s7r$T56SV!1qRAQa23"BbCS4 ?0ˏԜ#!e]qν6Ữ_mج" n7ٛN!N 5%hQԉu@TMIfb`oV-s6Tr9ٓM 4IHXͭHfeQVz5ЄJDF9rz ';ndשolDjoM8BgHb\iXVŮ;eEe3[4ѬVԨ m[mYJ"byƘd$"ԢJ JVMk޽vʟ]|3yaI"ZdIQ(E>1ӹLf&!\0Ǘweb[,i2:0l-: w#nA6_"B:ggi͝Y;\ ̣Vo!GDIa;l?·rBXu1.iDfTI8E'}m֋<࣪C)lk-HT3:6'5 =*#j=+..6L9#Kk_se!ݭnPE]e|*#.jţ\%!d !N:⎄$3"繶Srk\-%efZiob",[sDk5ņfOhjJyCe6z m?"͚1ƳGbϘ^R/w8UMآ'*izY2M='8<K#蓴x|:R J_h7 m]73.T}Nk=Y)_Nn˝xU&$cs\LiK OOϤD6X:*5$eRS7Usٌ3RIj^l~=;?zsIEp&SKu-Hq"娺16*2EF 1VRITt?H mI,C#^l߳n3ڬIh&"1R|ԣZJ|L%iGanᜫ(eQc/ˡ狦Cb'u^9JĮbG%e ]H#WV][ 37]~rH&꒺8Md-0n1Lˡd(/gݰ/'*ȣ5a*$;''J5:ó,&ᣩX⸔;%Ne+٭+%W5"ѳeOt/W{myĮYd\pb94J59>rM?cF{ޭl\-/D'SjGE>&FGyL>J޺דןʄ?nG'~ߛ'>~lWvٗ7rdxM/lW@++1'*-^l?3 XM+ť'QFeTD{:/oAH{uL3LԷ\B&b}㺟\mŦG\,˩h)jEjmUm+DY<%cLVe2|n=ۢUq%~AY hH:E &FmN⎄ gC֊Ƴ;a Uw Lll [dz\ܻy/Wa?Lt~V!1gc&#ɵi${rKiRO)?E~#(3o-tMJ7_ΩꑋSO»<2Q4"y:=Yp["JZq5Y+IfʽY2OܛVHn+SŤ*ЖOMz aohJТRDiQH7q|͓Qgur;Di"'4?@4p%dOvտWy|o&n>5ҙ2. )u"b"&u <}7_q-4jZ̒ЪgØ"f#6M݄Ftr6_q.<=7Ӓt̋n(h+^m߳nɶ vk(e%%EDddbm]b+4gS,ˣ(ԭSm3VtҒ.'V 2m׏=n 0{ ]f}4I>Ǝu\s)4Yib>Pd ?۷d o?xbo͓f?UCr+PlOb9c2?&cZ@7!e{VMO%T=(QԨWiDžE }KF(Ƅ%JZR"I""*Ͱww:x ;oqh"F蒛K!MҊRT22?Pjƒ0IOîU,ȋR2:"._D='j;|ӎ~[r{!فCYRn meUt4֨+1G/emRHiArJRT"/[4_Cc '#?]{<[AP!Ga픢·BN+oQi3[}6e_IPz[jl9ajۯ )0\p(UȎ4z^8љs>ĩGJL䱷q-><ț)8 ӮqY[#Z{37]T~cƂ!뻴Mb&fby'6GN>ziSo:/:ʻ6+ҕjPٟUEbVY%wL&5؎kRuOU1ͳqӶf;m|[J풋K:iխEL1SiiRwj׎hOƥGOŢ7Rkbq)OȺ:~^Rc8+ w7:bk~rR\DF1H{qNKqCTQ[ΪI)JBLj6Ue\oVK6),'3JKq)KY7D\ M%՘࣪ ^A'Ş4WZ.. Fu>V\m5-\j{+,޽_p4m$RDFe.N~k*r frjBԢC,GDÇxg=oL|< ͈ܦu9S&mlT3.k$u ŹKtڵ[ e %f\DGO0?$%)*%%2mZPJH"! p}^z^kOk_ꖊBymLuF8^|TOT};|Oq]*_|Rzv/||T:^=w}uI<{%RӰy{K'`ω?kKON~y/T>'/=;]*崥/ɴվ:=ɒ}u<{%RӰy{K'`ω?kKON~y/T>'/=;]*崥/ɴվ:=ɒ}u<{%RӰy{K'`ω?kKON~y/T>'/=;]*崥/ɴվ:=ɒ}u<{%RӰy{K'`ω?kKON~y/T>'/=;]*崥/ɴվ:=ɒ}u<ݸ΍>%?h.6ZE:i:(H:5ax|Vb ].{4F]n>ǤϮ#I:<2ڕ[u).ۈTgH/_Of_i9zJ5Ϳx*\eI'k-"462'GN^u.bymJOi½a%&m.rW)֦aM$=MJ"=4WOHLf{M_k^y[GfSZ7J4ׅtً']"tD=u[1$Ir$J4+JMKE͋y=bt qVUqovlv丘ۤRQkZLIfT-c5+QV'!/0ɣ䙍̘{;|hO*qꥧӃ9k/?U_&^ԉ֧Q AITR]-OF=e~)Ի&5`-믲Ry%!5\ܜSZVt÷>72%еnϰ𻤉u*-1dz۰ڊ1;A<&ek+1_e6^u-TTbpqV{ںrѤ.Z]֫GYSlHh%Iˣs 4YrSmM`(&'F}]"t7^LbX50-nQ* )Sf}5rhx+DEȸq)8,y%ڐq'GyvU줰umtq2?LN ]5yjvulaۭhbymҕ%JIW|Dggz&+[mvvؤe-gWim$32E[iHbP, jbk&-2X})uZdҪe&& SJYnۻDdedDiUBgV";Tm,<ՒXƘQ26zΨԒşOD >  Heading 2$@& 5CJ\DA D Default Paragraph FontViV  Table Normal :V 44 la (k (No List 6U`6 0 Hyperlink >*B*ph2>2 Title$a$5\8B@8 Body Text 5CJ\4"4 3*Header  !4 24 3*Footer  !HBH  3; Balloon TextCJOJQJ^JaJH`RH l  No SpacingCJ_HaJmH sH tH *W`a* Strong5\B' qB >pComment ReferenceCJaJ<< >p0 Comment TextCJaJ:: >p0Comment Text Char@j@ >pComment Subject5\F/F >pComment Subject Char5\P@P  List Paragraph ^m$ CJOJQJ>/> KHNo Spacing CharCJaJbOb <7hSection Note Red!B*CJOJPJQJ^JaJphPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭Vc:E3v@P~Ds |w< ": z B"L!-#V&()+l243567;p?"B"$%'()*,-./02345678:;<=>@A $-88@"B#&+19?B./2/":Xl,R$݄"w7"DL 8@T(    A?p "1101583v1v1Picture 2http://nagc.multiview.com/userlogo/nagc/1101583v1v1.jpg3"?B S  ?":K ",p@::::::::#:uUv hsRRR`k!,u!u!v!v!""**^*i*708011u1v1}1~1111111f2g22235559999:::::::::::#:uUv hsRRR`k!,u!u!v!v!""**^*i*708011u1v1}1~1111111f2g22235559999:#: |@. }|v t0 H H%"7 W0A"X9,G8HUnMi4_@gƪitp"9vh^`OJPJQJ^Jo(-h^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHhp^p`OJQJo(hHh@ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhP^P`OJQJo(hHh ^ `OJQJ^Jo(hHoh^`OJQJo(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo(h ^`hH.h p^p`hH.h @ L^@ `LhH.h ^`hH.h ^`hH.h L^`LhH.h ^`hH.h P^P`hH.h  L^ `LhH.h h^h`5hH.h 8^8`hH.h L^`LhH.h  ^ `hH.h  ^ `hH.h xL^x`LhH.h H^H`hH.h ^`hH.h L^`LhH. ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo( r ^r `OJQJo(B^B`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o ^`OJQJo(^`5o(.h ^`hH.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.^`o(.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.hp^p`OJQJo(hHh@ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhP^P`OJQJo(hHh ^ `OJQJ^Jo(hHoh^`OJQJo(hH ^`OJQJo(^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( ^`OJ QJ o(c^`OJQJ^Jo(o p^p`OJQJo( @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o P^P`OJQJo( itp|9v"X9"7nMG8H  }|_@g0 vP                                                     6.g                                   \        > q12,V>xF"b|.'j3vW1 6  "\ a Y j`QKHwNFPwyfVt^kNl x!s"$r#$C$wX%+L'q[([)3*1+S,S;7 3;<`O<O?|?@'@2@>Bd!C$E)HIHdI N'SwU%VsW WZvsZ[@~]9`\`m`eb dpd<7h i5iCjsjkClDrlkm>f%!9vSJ 4G b^w50jP`6B -E!2f t5L$1y-O!N,W)o?q.!k ;U{uUl7Q IHGIUfIp7::@":@Unknown q.[x Times New RomanTimes New Roman PSMT5Symbol3. .Cx Arial5..[`)TahomaE. Century GothicK&  [ @(Open SansVerdanaG.*{$ CalibriCalibri?=.Cx Courier New;Wingdings9 WebdingsA$BCambria Math"1h ۈ ۈJg0 0tq0 0tq499 2qHP ?xF2! xxԩX Skidmore Collegenewuser Mary Hoehn8         Oh+'0  0 < H T`hpx91newuser Normal.dotm Mary Hoehn3Microsoft Office Word@Ik@/@6_|@N|0 0 ՜.+,D՜.+,L hp  91qt9 91 Title 8@ _PID_HLINKSApf]mailto:mhoehn@skidmore.edu  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSUVWXYZ[\]^_`abcdefghijklmnopqrstuvxyz{|}~Root Entry F7|1TableTEWordDocument0SummaryInformation(wDocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q